151
|
Geller R, Taguwa S, Frydman J. Broad action of Hsp90 as a host chaperone required for viral replication. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2011; 1823:698-706. [PMID: 22154817 DOI: 10.1016/j.bbamcr.2011.11.007] [Citation(s) in RCA: 159] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2011] [Revised: 11/21/2011] [Accepted: 11/22/2011] [Indexed: 02/06/2023]
Abstract
Viruses are intracellular pathogens responsible for a vast number of human diseases. Due to their small genome size, viruses rely primarily on the biosynthetic apparatus of the host for their replication. Recent work has shown that the molecular chaperone Hsp90 is nearly universally required for viral protein homeostasis. As observed for many endogenous cellular proteins, numerous different viral proteins have been shown to require Hsp90 for their folding, assembly, and maturation. Importantly, the unique characteristics of viral replication cause viruses to be hypersensitive to Hsp90 inhibition, thus providing a novel therapeutic avenue for the development of broad-spectrum antiviral drugs. The major developments in this emerging field are hereby discussed. This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).
Collapse
Affiliation(s)
- Ron Geller
- Department of Biology and BioX Program, Stanford University, Stanford, CA, USA
| | | | | |
Collapse
|
152
|
Abstract
This article was based on a presentation given at the 26th International Pediatric Association Conference of Pediatrics, Johannesburg, South Africa, 4-9 August 2010. In 2009, there were 9.4 million new cases of tuberculosis (TB) globally, and, of these, approximately 1 million were pediatric cases. Drug-resistant TB makes up a relatively small proportion of new TB cases, but is much more likely in previously treated cases. Pediatric TB remains difficult to diagnose microbiologically, with the result that detection of drug-resistant TB in children is an ongoing challenge. Since children diagnosed with TB predominantly represent recently acquired TB infection, they provide an important indication of drug-resistant TB prevalence and transmission within their communities. Drug-resistant TB is essentially a man-made problem, which consumes large amounts of healthcare resources. Recent technologic advances may pave the way to more rapid and accurate diagnosis of TB in children. Similarly, these advances are likely to result in improved detection of drug-resistant pediatric TB isolates. The treatment of pediatric drug-resistant TB requires prolonged courses of expensive and potentially toxic drugs, many of which are not available in child-friendly formulations. New anti-TB drugs are at various stages of pre-clinical development and will hopefully allow for shorter, more effective treatment regimens in the not too distant future. HIV-infected children are at extremely high risk for TB acquisition and subsequent progression to symptomatic disease; therefore, many cases of pediatric drug-resistant TB occur in HIV-infected children. This often results in complicated pharmacologic regimens (including anti-TB and antiretroviral drugs) that are difficult to comply with and may have unpredictable interactions. There are limited reports of long-term clinical outcomes of children diagnosed with drug-resistant TB, but improvements in the diagnosis and pharmacologic management of these cases have the potential to improve the quality of care offered to these children.
Collapse
Affiliation(s)
- Gary Reubenson
- Department of Paediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Gauteng, South Africa.
| |
Collapse
|
153
|
Dietz I, Jerchel S, Szaszák M, Shima K, Rupp J. When oxygen runs short: the microenvironment drives host-pathogen interactions. Microbes Infect 2011; 14:311-6. [PMID: 22133978 DOI: 10.1016/j.micinf.2011.11.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2011] [Revised: 11/07/2011] [Accepted: 11/07/2011] [Indexed: 01/13/2023]
Abstract
Pathogens that colonize or infect the human body have to face varying oxygen concentrations within different organs. Inflammation itself promotes oxygen consumption within affected tissues and creates a low oxygen environment. As a consequence, pathogens and the host immune system have to adapt to rapid changes in oxygen availability. Here we summarize recent findings on the adaptation of pathogens, host defense mechanisms and treatment strategies against intracellular pathogens in a low oxygen environment.
Collapse
Affiliation(s)
- Inga Dietz
- Institute of Medical Microbiology and Hygiene, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
| | | | | | | | | |
Collapse
|
154
|
Huijben S, Sim DG, Nelson WA, Read AF. The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection. J Evol Biol 2011; 24:2410-22. [PMID: 21883612 PMCID: PMC3304104 DOI: 10.1111/j.1420-9101.2011.02369.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Malaria infections normally consist of more than one clonally replicating lineage. Within-host interactions between sensitive and resistant parasites can have profound effects on the evolution of drug resistance. Here, using the Plasmodium chabaudi mouse malaria model, we ask whether the costs and benefits of resistance are affected by the number of co-infecting strains competing with a resistant clone. We found strong competitive suppression of resistant parasites in untreated infections and marked competitive release following treatment. The magnitude of competitive suppression depended on competitor identity. However, there was no overall effect of the diversity of susceptible parasites on the extent of competitive suppression or release. If these findings generalize, then transmission intensity will impact on resistance evolution because of its effect on the frequency of mixed infections, not because of its effect on the distribution of clones per host. This would greatly simplify the computational problems of adequately capturing within-host ecology in models of drug resistance evolution in malaria.
Collapse
Affiliation(s)
- S Huijben
- Department of Biology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA.
| | | | | | | |
Collapse
|
155
|
Antibiotics and the resistant microbiome. Curr Opin Microbiol 2011; 14:556-63. [DOI: 10.1016/j.mib.2011.07.005] [Citation(s) in RCA: 117] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Accepted: 07/02/2011] [Indexed: 11/19/2022]
|
156
|
Djouhri-Bouktab L, Vidal N, Rolain JM, Brunel JM. Synthesis of New 3,20-Bispolyaminosteroid Squalamine Analogues and Evaluation of Their Antimicrobial Activities. J Med Chem 2011; 54:7417-21. [DOI: 10.1021/jm200506x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Lamia Djouhri-Bouktab
- Laboratoire URMITE UMR 6236 CNRS, Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27 Boulevard Jean Moulin, 13385 Marseille 05, France
| | - Nicolas Vidal
- UPCAM iSm2, Case 342, Aix-Marseille Université, Avenue Escadrille Normandie Niémen, 13397 Marseille cedex 13, France
| | - Jean Marc Rolain
- Laboratoire URMITE UMR 6236 CNRS, Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27 Boulevard Jean Moulin, 13385 Marseille 05, France
| | - Jean Michel Brunel
- Laboratoire URMITE UMR 6236 CNRS, Faculté de Médecine et de Pharmacie, Aix-Marseille Université, 27 Boulevard Jean Moulin, 13385 Marseille 05, France
| |
Collapse
|
157
|
Chao DL, Bloom JD, Kochin BF, Antia R, Longini IM. The global spread of drug-resistant influenza. J R Soc Interface 2011; 9:648-56. [PMID: 21865253 DOI: 10.1098/rsif.2011.0427] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Resistance to oseltamivir, the most widely used influenza antiviral drug, spread to fixation in seasonal influenza A(H1N1) between 2006 and 2009. This sudden rise in resistance seemed puzzling given the low overall level of the oseltamivir usage and the lack of a correlation between local rates of resistance and oseltamivir usage. We used a stochastic simulation model and deterministic approximations to examine how such events can occur, and in particular to determine how the rate of fixation of the resistant strain depends both on its fitness in untreated hosts as well as the frequency of antiviral treatment. We found that, for the levels of antiviral usage in the population, the resistant strain will eventually spread to fixation, if it is not attenuated in transmissibility relative to the drug-sensitive strain, but not at the speed observed in seasonal H1N1. The extreme speed with which the resistance spread in seasonal H1N1 suggests that the resistant strain had a transmission advantage in untreated hosts, and this could have arisen from genetic hitchhiking, or from the mutations responsible for resistance and compensation. Importantly, our model also shows that resistant virus will fail to spread if it is even slightly less transmissible than its sensitive counterpart--a finding of relevance given that resistant pandemic influenza (H1N1) 2009 may currently suffer from a small, but nonetheless experimentally perceptible reduction in transmissibility.
Collapse
Affiliation(s)
- Dennis L Chao
- Center for Statistics and Quantitative Infectious Diseases, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
| | | | | | | | | |
Collapse
|
158
|
Brites D, Gagneux S. Old and new selective pressures on Mycobacterium tuberculosis. INFECTION GENETICS AND EVOLUTION 2011; 12:678-85. [PMID: 21867778 DOI: 10.1016/j.meegid.2011.08.010] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2011] [Revised: 08/09/2011] [Accepted: 08/10/2011] [Indexed: 02/02/2023]
Abstract
Tuberculosis (TB) has been affecting humans for millennia. There is increasing indication that human-adapted Mycobacterium tuberculosis complex (MTBC) has been co-evolving with different human populations. Some of the most important drivers of MTBC evolution have been the host immune response and human demography. These old selective forces have shaped many of the features of human TB we see today. Two new selective pressures have emerged only a few decades ago, namely HIV co-infection and the use of anti-TB drugs. Here we discuss how the emergence of HIV/TB and drug resistance could impact the long-term balance between MTBC and its human host, and how these changes might influence the future evolutionary trajectory of MTBC.
Collapse
Affiliation(s)
- Daniela Brites
- Swiss Tropical and Public Health Institute, Basel, Switzerland
| | | |
Collapse
|
159
|
Comas I, Gagneux S. A role for systems epidemiology in tuberculosis research. Trends Microbiol 2011; 19:492-500. [PMID: 21831640 DOI: 10.1016/j.tim.2011.07.002] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2011] [Revised: 07/05/2011] [Accepted: 07/12/2011] [Indexed: 10/17/2022]
Abstract
Despite being a curable disease, tuberculosis (TB) killed more people in 2009 than during any previous year in history. Progress in TB research has been slow, and remains burdened by important gaps in our knowledge of the basic biology of Mycobacterium tuberculosis, the causative agent of TB, and its interaction with the human host. Fortunately, major systems biology initiatives have recently been launched that will help fill some of these gaps. However, to fully comprehend TB and control this disease globally, current systems biological approaches will not suffice. The influence of host and pathogen diversity, changes in human demography, and socioeconomic and environmental factors will also need to be considered. Such a multidisciplinary approach might be best described as 'systems epidemiology' in an effort to overcome the traditional boundaries between basic biology and classical epidemiology.
Collapse
Affiliation(s)
- Iñaki Comas
- Division of Mycobacterial Research, MRC National Institute for Medical Research, London, UK
| | | |
Collapse
|
160
|
Borrell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2011; 17:815-20. [PMID: 21682802 DOI: 10.1111/j.1469-0691.2011.03556.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Mycobacterium tuberculosis harbours little DNA sequence diversity compared with other bacteria. However, there is mounting evidence that strain-to-strain variation in this organism has been underestimated. We review our current understanding of the genetic diversity among M. tuberculosis clinical strains and discuss the relevance of this diversity for the ongoing global epidemics of drug-resistant tuberculosis. Based on findings in other bacteria, we propose that epistatic interactions between pre-existing differences in strain genetic background, acquired drug-resistance-conferring mutations and compensatory changes could play a role in the emergence and spread of drug-resistant M. tuberculosis.
Collapse
Affiliation(s)
- S Borrell
- Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland University of Basel, Basel, Switzerland
| | | |
Collapse
|
161
|
The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci U S A 2011; 108 Suppl 2:10871-7. [PMID: 21690376 DOI: 10.1073/pnas.1100299108] [Citation(s) in RCA: 183] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The evolution of drug-resistant pathogens is a major challenge for 21st century medicine. Drug use practices vigorously advocated as resistance management tools by professional bodies, public health agencies, and medical schools represent some of humankind's largest attempts to manage evolution. It is our contention that these practices have poor theoretical and empirical justification for a broad spectrum of diseases. For instance, rapid elimination of pathogens can reduce the probability that de novo resistance mutations occur. This idea often motivates the medical orthodoxy that patients should complete drug courses even when they no longer feel sick. Yet "radical pathogen cure" maximizes the evolutionary advantage of any resistant pathogens that are present. It could promote the very evolution it is intended to retard. The guiding principle should be to impose no more selection than is absolutely necessary. We illustrate these arguments in the context of malaria; they likely apply to a wide range of infections as well as cancer and public health insecticides. Intuition is unreliable even in simple evolutionary contexts; in a social milieu where in-host competition can radically alter the fitness costs and benefits of resistance, expert opinion will be insufficient. An evidence-based approach to resistance management is required.
Collapse
|
162
|
Kouyos RD, Abel Zur Wiesch P, Bonhoeffer S. On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community. PLoS Pathog 2011; 7:e1001334. [PMID: 21533212 PMCID: PMC3077359 DOI: 10.1371/journal.ppat.1001334] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2010] [Accepted: 03/15/2011] [Indexed: 11/18/2022] Open
Abstract
The evolution of drug resistant bacteria is a severe public health problem, both in hospitals and in the community. Currently, some countries aim at concentrating highly specialized services in large hospitals in order to improve patient outcomes. Emergent resistant strains often originate in health care facilities, but it is unknown to what extent hospital size affects resistance evolution and the resulting spillover of hospital-associated pathogens to the community. We used two published datasets from the US and Ireland to investigate the effects of hospital size and controlled for several confounders such as antimicrobial usage, sampling frequency, mortality, disinfection and length of stay. The proportion of patients acquiring both sensitive and resistant infections in a hospital strongly correlated with hospital size. Moreover, we observe the same pattern for both the percentage of resistant infections and the increase of hospital-acquired infections over time. One interpretation of this pattern is that chance effects in small hospitals impede the spread of drug-resistance. To investigate to what extent the size distribution of hospitals can directly affect the prevalence of antibiotic resistance, we use a stochastic epidemiological model describing the spread of drug resistance in a hospital setting as well as the interaction between one or several hospitals and the community. We show that the level of drug resistance typically increases with population size: In small hospitals chance effects cause large fluctuations in pathogen population size or even extinctions, both of which impede the acquisition and spread of drug resistance. Finally, we show that indirect transmission via environmental reservoirs can reduce the effect of hospital size because the slow turnover in the environment can prevent extinction of resistant strains. This implies that reducing environmental transmission is especially important in small hospitals, because such a reduction not only reduces overall transmission but might also facilitate the extinction of resistant strains. Overall, our study shows that the distribution of hospital sizes is a crucial factor for the spread of drug resistance. The increasing spread of bacteria, which are resistant to antibiotics, is a serious threat to clinical care. Currently, several countries aim at concentrating highly specialized services in large hospitals in order to improve patient outcomes. However, empirical studies have shown that resistance levels correlate with hospital size. To illustrate this correlation, we analyze two published datasets from the US and Ireland and controlled for antimicrobial usage, disinfection and length of stay. The proportion of patients acquiring both sensitive and resistant infections in hospitals strongly correlated with hospital size. Moreover, we observe the same pattern for both the percentage of resistant infections and the temporal increase of hospital-acquired infections. To investigate to what extent hospital size can directly affect the prevalence of antibiotic resistance, we use mathematical models describing the epidemic spread of resistance in hospitals and the community. We find that small hospitals typically lead to considerably lower resistance levels than large hospitals. However, this beneficial effect of small hospital size may be reduced if bacteria are transmitted indirectly via the environment. Therefore, reducing environmental transmission might be particularly important in small hospitals. Overall, our findings suggest that the short-term benefits of larger hospitals may come at the price of increasing resistance in the long term.
Collapse
Affiliation(s)
- Roger D Kouyos
- Institute of Integrative Biology, ETH Zurich, Zurich, Switzerland.
| | | | | |
Collapse
|
163
|
Nilsen E. Bør azitromycindoseringen endres? TIDSSKRIFT FOR DEN NORSKE LEGEFORENING 2011; 131:1415. [DOI: 10.4045/tidsskr.11.0605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
|